The COMBINE SAFTEE: A structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field

Bankole A. Johnson, Nassima Ait-Daoud, John D Roache

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: In the many clinical studies conducted in the alcoholism field with psychotropic drugs-and throughout the drug development field in medicine, where evaluation of adverse events can be incomplete, arbitrary or misleading-few standardized methods have been developed for assessing adverse events, whereas defining standardized methods for evaluating clinical efficacy is typical. For the National Institute on Alcohol Abuse and Alcoholism COMBINE Study, testing the safety and efficacy of naltrexone and acamprosate, both alone and in combination, in the treatment of alcohol dependence, we adapted a standardized instrument-the Systematic Assessment for Treatment Emergent Events (SAFTEE)-for assessing adverse events in these Phase 2- to Phase 3-type studies. Method: We standardized use of the SAFTEE with training, supervision and clear guidelines for its implementation, including development of a nomenclature for the typical adverse events associated with these medications and a format for examining symptom severity. Data from the COMBINE SAFTEE include not only frequency of adverse events but also severity level and a composite index taking into account both the severity and duration of symptoms. Results: The COMBINE SAFTEE was incorporated into the Medical Management therapy and showed high fidelity with its utility, consistency of deliverability and flexibility in measuring adverse events in both the human laboratory and clinical trial settings using intervals that varied from daily to weekly use. Conclusions: Due to its high standardization level, the COMBINE SAFTEE could be incorporated into other brief compliance enhancement strategies in clinical studies to assess the efficacy of putative therapeutic drugs.

Original languageEnglish (US)
Pages (from-to)157-167
Number of pages11
JournalJournal of Studies on Alcohol
Volume66
Issue numberSUPPL. 15
StatePublished - Aug 2005

Fingerprint

alcoholism
Alcoholism
Alcohols
Naltrexone
event
Psychotropic Drugs
National Institute on Alcohol Abuse and Alcoholism (U.S.)
Terminology
Pharmaceutical Preparations
Standardization
Medicine
Compliance
Composite materials
Testing
Clinical Trials
Guidelines
Safety
Therapeutics
Clinical Studies
alcohol

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychology(all)

Cite this

The COMBINE SAFTEE : A structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. / Johnson, Bankole A.; Ait-Daoud, Nassima; Roache, John D.

In: Journal of Studies on Alcohol, Vol. 66, No. SUPPL. 15, 08.2005, p. 157-167.

Research output: Contribution to journalArticle

@article{c537873e3cb04169b451b4f091813463,
title = "The COMBINE SAFTEE: A structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field",
abstract = "Objective: In the many clinical studies conducted in the alcoholism field with psychotropic drugs-and throughout the drug development field in medicine, where evaluation of adverse events can be incomplete, arbitrary or misleading-few standardized methods have been developed for assessing adverse events, whereas defining standardized methods for evaluating clinical efficacy is typical. For the National Institute on Alcohol Abuse and Alcoholism COMBINE Study, testing the safety and efficacy of naltrexone and acamprosate, both alone and in combination, in the treatment of alcohol dependence, we adapted a standardized instrument-the Systematic Assessment for Treatment Emergent Events (SAFTEE)-for assessing adverse events in these Phase 2- to Phase 3-type studies. Method: We standardized use of the SAFTEE with training, supervision and clear guidelines for its implementation, including development of a nomenclature for the typical adverse events associated with these medications and a format for examining symptom severity. Data from the COMBINE SAFTEE include not only frequency of adverse events but also severity level and a composite index taking into account both the severity and duration of symptoms. Results: The COMBINE SAFTEE was incorporated into the Medical Management therapy and showed high fidelity with its utility, consistency of deliverability and flexibility in measuring adverse events in both the human laboratory and clinical trial settings using intervals that varied from daily to weekly use. Conclusions: Due to its high standardization level, the COMBINE SAFTEE could be incorporated into other brief compliance enhancement strategies in clinical studies to assess the efficacy of putative therapeutic drugs.",
author = "Johnson, {Bankole A.} and Nassima Ait-Daoud and Roache, {John D}",
year = "2005",
month = "8",
language = "English (US)",
volume = "66",
pages = "157--167",
journal = "Journal of Studies on Alcohol and Drugs",
issn = "1937-1888",
publisher = "Alcohol Research Documentation, Inc.",
number = "SUPPL. 15",

}

TY - JOUR

T1 - The COMBINE SAFTEE

T2 - A structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field

AU - Johnson, Bankole A.

AU - Ait-Daoud, Nassima

AU - Roache, John D

PY - 2005/8

Y1 - 2005/8

N2 - Objective: In the many clinical studies conducted in the alcoholism field with psychotropic drugs-and throughout the drug development field in medicine, where evaluation of adverse events can be incomplete, arbitrary or misleading-few standardized methods have been developed for assessing adverse events, whereas defining standardized methods for evaluating clinical efficacy is typical. For the National Institute on Alcohol Abuse and Alcoholism COMBINE Study, testing the safety and efficacy of naltrexone and acamprosate, both alone and in combination, in the treatment of alcohol dependence, we adapted a standardized instrument-the Systematic Assessment for Treatment Emergent Events (SAFTEE)-for assessing adverse events in these Phase 2- to Phase 3-type studies. Method: We standardized use of the SAFTEE with training, supervision and clear guidelines for its implementation, including development of a nomenclature for the typical adverse events associated with these medications and a format for examining symptom severity. Data from the COMBINE SAFTEE include not only frequency of adverse events but also severity level and a composite index taking into account both the severity and duration of symptoms. Results: The COMBINE SAFTEE was incorporated into the Medical Management therapy and showed high fidelity with its utility, consistency of deliverability and flexibility in measuring adverse events in both the human laboratory and clinical trial settings using intervals that varied from daily to weekly use. Conclusions: Due to its high standardization level, the COMBINE SAFTEE could be incorporated into other brief compliance enhancement strategies in clinical studies to assess the efficacy of putative therapeutic drugs.

AB - Objective: In the many clinical studies conducted in the alcoholism field with psychotropic drugs-and throughout the drug development field in medicine, where evaluation of adverse events can be incomplete, arbitrary or misleading-few standardized methods have been developed for assessing adverse events, whereas defining standardized methods for evaluating clinical efficacy is typical. For the National Institute on Alcohol Abuse and Alcoholism COMBINE Study, testing the safety and efficacy of naltrexone and acamprosate, both alone and in combination, in the treatment of alcohol dependence, we adapted a standardized instrument-the Systematic Assessment for Treatment Emergent Events (SAFTEE)-for assessing adverse events in these Phase 2- to Phase 3-type studies. Method: We standardized use of the SAFTEE with training, supervision and clear guidelines for its implementation, including development of a nomenclature for the typical adverse events associated with these medications and a format for examining symptom severity. Data from the COMBINE SAFTEE include not only frequency of adverse events but also severity level and a composite index taking into account both the severity and duration of symptoms. Results: The COMBINE SAFTEE was incorporated into the Medical Management therapy and showed high fidelity with its utility, consistency of deliverability and flexibility in measuring adverse events in both the human laboratory and clinical trial settings using intervals that varied from daily to weekly use. Conclusions: Due to its high standardization level, the COMBINE SAFTEE could be incorporated into other brief compliance enhancement strategies in clinical studies to assess the efficacy of putative therapeutic drugs.

UR - http://www.scopus.com/inward/record.url?scp=23944459585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944459585&partnerID=8YFLogxK

M3 - Article

C2 - 16223067

AN - SCOPUS:23944459585

VL - 66

SP - 157

EP - 167

JO - Journal of Studies on Alcohol and Drugs

JF - Journal of Studies on Alcohol and Drugs

SN - 1937-1888

IS - SUPPL. 15

ER -